Phase 2 COVID-19 trial
The US Food and Drug Administration (FDA) has cleared a pivotal phase 2 trial of ViralClear’s investigational antiviral merimepodib in patients hospitalised with COVID-19.

Two thalassaemia charities have reported that Bluebird Bio’s gene therapy for the disease has been approved in the EU – although that seems to be news to the company.

Migraine drug
Becomes second drugmaker to bring an oral CGRP inhibitor to US market

De Europese Commissie (EC) heeft handelsvergunning verleend voor Yeytuo (lenacapavir) van Gilead Sciences. Het is de eerste tweemaal per jaar toegediende injecteerbare behandeling die in de Europese Unie (EU) is...